First human test of new brain cancer drug targets genetic flaw
NCT ID NCT03030066
Summary
This is an early-stage study to test the safety and initial effects of an experimental drug called DS-1001b in adults with recurrent glioma, a type of brain tumor. The drug specifically targets tumors that have a particular genetic change called an IDH1-R132 mutation. The main goals are to find a safe dose and see how the body processes the drug, while also checking for any early signs that it might help control the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.